Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Aadi Bioscience Inc. - news published 202 - readings 2.016

BACK

Aadi Bioscience Inc.

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company (Form 8-K)

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasd ...

18.03.2025

Aadi Bioscience Inc.

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial ...

18.03.2025

Aadi Bioscience Inc.

Notice of Sales of Unregistered Securities (Form D)

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D Notice of Exempt Offering of Securities OMB APPROVAL OMB Number: 3235- ...

18.03.2025

Aadi Bioscience Inc.

Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

MORRISTOWN, N.J. , March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscie ...

14.03.2025

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

06.03.2025

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

05.03.2025

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.03.2025

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.03.2025

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.03.2025

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.03.2025

Aadi Bioscience Inc.

Aadi Bioscience Announces Closing of $100 Million PIPE Financing (Form 8-K)

Aadi Bioscience Announces Closing of $100 Million PIPE Financing MORRISTOWN, NJ, March 4, 2025 /PRNewswire/ - Aadi Bioscience, Inc. (Nasdaq: AADI)("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private pla ...

04.03.2025

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.03.2025

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.03.2025

Aadi Bioscience Inc.

Aadi Corporate Presentation

Corporate Presentation March 3, 2025 Overview of Transactions Transformative Transactions Rooted in Aadi Long-Term Vision FYARRO Sale ADC Portfolio PIPE Financing Kaken Pharmaceuticals to purchase FYARRO and associated infrastructure for $100M In-licensing 3 ADC assets from WuXi Biologics leveraging advanced linker-payload technology from Hangzhou DAC Private financing of $100 ...

03.03.2025

Aadi Bioscience Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- ...

19.02.2025

Aadi Bioscience Inc. - news published 202 - readings 2.016

Aadi Bioscience Inc.

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company (Form 8-K)

Aadi Bioscience Inc.

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company

Aadi Bioscience Inc.

Notice of Sales of Unregistered Securities (Form D)

Aadi Bioscience Inc.

Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Aadi Bioscience Inc.

Aadi Bioscience Announces Closing of $100 Million PIPE Financing (Form 8-K)

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Aadi Bioscience Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Aadi Bioscience Inc.

Aadi Corporate Presentation

Aadi Bioscience Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member